Clinical trial NCT00719836: A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
Official title: A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndromes
Myelofibrosis
Keywords: SB1518
Chronic Idiopathic Myelofibrosis
JAK2 Inhibitor
Lead sponsor: S*BIO
Sponsor class: INDUSTRY
First posted: 2008-07-22
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study consists of two phases: the first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with advanced myeloid malignancies; the second portion of the study is a Phase 2 study to define the efficacy and safety profile of single-agent SB1518 at the recommended dose in subjects with chronic idiopathic myelofibrosis (CIMF).


Eligibility criteria: Inclusion Criteria

* During the dose escalation phase: subjects with histologically confirmed myeloid malignancy who have failed standard therapies or are not candidates for palliative therapies. This includes the following:

  * Subjects with Acute Myelogenous Leukemia (AML)
  * Subjects with Chronic Myelogenous Leukemia (CML) in accelerated phase
  * Subjects with Chronic Myelogenous Leukemia (CML) in blast crisis
  * Subjects with high-risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
  * Subjects with Advanced Myelofibrosis (MF)
  * In Phase 2, subjects with CIMF (as well as post ET/PV MF)
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* All men of reproductive potential and women of child-bearing potential must agree to practice effective contraception during the entire study period and for one month after the last study treatment, unless documentation of infertility exists. Additionally, women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study drug
* Able to understand and willing to sign the informed consent form

Exclusion Criteria

* Subjects with Chronic Myelogenous Leukemia (CML) in chronic phase;
* Uncontrolled inter-current illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as judged by treating physician. Subjects receiving antibiotics for infections that are under control may be included in the study;
* Concurrent malignancy, except those subjects with early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia are eligible for the study;
* Known HIV-positive (such subjects are at increased risk of lethal infections when treated with potentially marrow-suppressive therapy);
* Known active hepatitis A, B, or C;
* Women who are pregnant or lactating.

Primary outcomes:
measure: Phase 1: To establish the maximum tolerated dose of SB1518 as a single agent when administered orally daily in subjects with advanced myeloid malignancies
timeFrame: Throughout the study
measure: Phase 2: to assess the clinical benefit rate in subjects with CIMF who are treated with SB1518 at the recommended dose.
timeFrame: Throughout the study
Secondary outcomes:
measure: Assess the safety and tolerability of SB1518, administered once daily in subjects with advanced myeloid malignancies
timeFrame: Throughout the study
measure: Assess the pharmacokinetic and pharmacodynamic profile of SB1518
timeFrame: Throughout the study
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago Hospitals
state: Illinois
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Center
state: Washington
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Srdan Verstovsek, M.D, Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Fred Hutchinson Cancer Center
name: H. Joachim Deeg, M.D
role: PRINCIPAL_INVESTIGATOR
affiliation: The University of Chicago Hospitals
name: Olatoyosi M. Odenike, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016 Dec 8;9(1):137. doi: 10.1186/s13045-016-0367-x.